Dyadic International announced a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application 16/640,483, titled "PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA" (the “Patent”), and is expected to provide patent protection through 2038.
The Patent will cover claims for the development and manufacture of seasonal and pandemic influenza vaccines from the Company’s C1 protein production platform. The human influenza vaccine market is currently valued at approximately $8 Billion USD and expected to grow to over $12 by 2028 with multi-valent vaccines leading the market.
“The COVID pandemic has provided important insights in the fight against infectious diseases. There is an urgent need for more efficient manufacturing platforms that can rapidly and affordably produce more complex vaccines, in greater quantities, to address a global rather than regional population. The need is for humans, and with the recent outbreak of Avian Flu, for animal health as well,” said Mark Emalfarb, Chief Executive Officer of Dyadic.
“Data presented at the World Vaccine Conference earlier this month demonstrated the capability of C1 to produce flu and other antigens. We believe C1 has the potential to become a global solution for seasonal or pandemic rapid production, at affordable costs for developed and emerging countries, and for mono or multi-valent vaccines,” continued Mr. Emalfarb.
“Along with our robust patent estate for the C1-cell line, the Patent strengthens our intellectual property portfolio around innovations for our proprietary and patented C1-cell protein production platform, further supporting the research and production of antigens, antibodies, and other therapeutic proteins for infectious and other diseases such as oncology, diabetes, arthritis, and neurological diseases from filamentous fungi. Dyadic has amassed a patent family around genetically engineered hyper productive C1-cells, supported by a variety of novel, pending and protected inventions,” concluded Mr. Emalfarb.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!